Grants per year
Search results
-
Prot# A3921035: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled Active Comparator, Multicenter Study to Compare 5 Dose Regimens of CP-690,550 and Adalimumab versus Placebo, Administered for 6 Months in the Treatment of Subjects with Active Rheum
Ruderman, E. M. (PD/PI)
ICON Clinical Research, LLC, Pfizer Inc.
2/27/08 → 2/27/11
Project: Research project
-
Prot# A 9391010: A Phase 2, Randomized, Double-Blind Assessment of Efficacy and Safety of PF-04171327(1, 5, 10, 15 MG Dose, Daily) Compared to 5 MG and 10 MG Prednisone Daily and Placebo Daily in Subjects with Rheumatoid Arthritis Over an 8 Week Period Fo
Ruderman, E. M. (PD/PI)
11/8/11 → 11/8/14
Project: Research project
-
Prot#ABX-0206: A Multi-center, Placebo-Controlled, Parallel-Group Double-Blind Study to Assess the Safety and Efficacy of ABX-IL8 in Rheumatoid Arthritis Patients
Ruderman, E. M. (PD/PI)
5/25/01 → 4/10/07
Project: Research project
-
Prot#ABX-0206: A Multi-center, Placebo-Controlled, Parallel-Group Double-Blind Study to Assess the Safety and Efficacy of ABX-IL8 in Rheumatoid Arthritis Patients
Ruderman, E. M. (PD/PI)
5/25/01 → 4/10/07
Project: Research project
-
Prot #ACT013: Drug Development in the Arthritis/Atherosclerosis Mouse
Perlman, H. R. (PD/PI) & Misharin, A. (Co-PD/PI)
6/17/13 → 9/1/14
Project: Research project
-
Prot #AMP-002: A Randomized, Double-Blind, Active Comparator-Controlled, Crossover Study to Assess the Capacity of Delayed-Release Prednisone (RAYOS®) Compared to Immediate-Release Prednisone to Improve Fatigue and Control Morning Symptoms in Subjects wit
Mahieu, M. A. (PD/PI)
9/5/17 → 6/1/21
Project: Research project
-
Prot# ARRAY-797-103: A Phase Ib, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Pharmacokinetics, Safety and Efficacy of ARRY-371797 in Patients with Rheumatoid Arthritis (RA) Receiving Stable Doses of Methotrexate (MTX)
Ruderman, E. M. (PD/PI)
9/9/08 → 9/9/11
Project: Research project
-
Prot# ARRAY-797-201: A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study to Investigate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of 12 Weeks of Treatment with ARRY-371797 in Patients with Active A
Ruderman, E. M. (PD/PI)
3/11/09 → 3/10/12
Project: Research project
-
Prot #CAB-201-001: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Systemic Lupus Erythematosus
Blanco, I. (PD/PI), Wadhwani, S. (PD/PI) & Wadhwani, S. (PD/PI)
2/26/24 → 8/30/27
Project: Research project
-
Prot #CAB-201-002: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Idiopathic Inflammatory Myopathy
Georges, G. E. (PD/PI), Hsieh, C. (PD/PI) & Hsieh, C. (Co-Investigator)
Advanced Clinical LLC, Cabaletta Bio, Inc.
1/22/24 → 5/21/24
Project: Research project
-
Prot #CAB-201-003: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Systemic Sclerosis
Georges, G. E. (PD/PI), Georges, G. E. (PD/PI) & Richardson, C. L. (Co-Investigator)
Advanced Clinical LLC, Cabaletta Bio, Inc.
4/1/24 → 9/13/27
Project: Research project
-
Prot #CC-10004-AS-001: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Active Ankylosing Spondylitis
Ruderman, E. M. (PD/PI)
PPD Development, Celgene Corporation
10/23/12 → 10/23/15
Project: Research project
-
Prot# CR10: Index for Rheumatoid Arthritis Measurement (InFoRM) Study
Ruderman, E. M. (PD/PI)
8/25/09 → 8/24/12
Project: Research project
-
Prot #EHP-101-SS01: A Phase IIa, Double-Blind, Randomised, Intracohort Placebo-Controlled, Multicentre Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101 in Patients with Diffuse Cutaneous Systemic Sclerosis
Richardson, C. L. (PD/PI)
Quintiles, Inc., Emerald Health Pharmaceuticals Australia Pty Ltd.
1/5/21 → 1/5/24
Project: Research project
-
Prot #ES-301: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
Correia, C. S. (PD/PI)
Medpace Clinical Research LLC, Eicos Sciences, Inc.
10/14/19 → 10/14/22
Project: Research project
-
Prot# GHO-09-1621: Lupus Impact Tracker: A Longitudinal Validation Study
Ramsey-Goldman, R. (PD/PI) & Hsieh, C. (Co-PD/PI)
Kendle International Inc., GlaxoSmithKline LLC
9/14/11 → 9/14/14
Project: Research project
-
Prot# GL02-01: A Randomized, Double-Blind, Multi-Center, Placebo Controlled Study to Assess Prevention of Bone Loss by Treatment with Gl701 (Prestara?) in Women with Systemic Lupus Erythematosus Receiving Treatment with Glucocorticoids
Ramsey-Goldman, R. (PD/PI)
1/31/03 → 8/21/10
Project: Research project
-
Prot# GL02-01: A Randomized, Double-Blind, Multi-Center, Placebo Controlled Study to Assess Prevention of Bone Loss by Treatment with Gl701 (Prestara?) in Women with Systemic Lupus Erythematosus Receiving Treatment with Glucocorticoids
Ramsey-Goldman, R. (PD/PI)
1/31/03 → 8/21/10
Project: Research project
-
Prot# GL03-01: A Multi-Center, Open-Label Study to Assess the Durability and Safety of the Prevention of Bone Loss by Treatment with GL701 (Prestara?) in Women with Systemic Lupus Erythematosus Receiving Treatment with Glucocorticoids
Ramsey-Goldman, R. (PD/PI)
9/22/04 → 12/22/04
Project: Research project
-
Prot #HGS1006-C1124: A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated with or without BENLYSTA™ (belimumab)
Hsieh, C. (PD/PI)
Outcome Sciences Inc., GlaxoSmithKline LLC
10/9/14 → 11/30/24
Project: Research project